Sulfaguanidine

The main ingredients and chemical names of this product are: sulfaguanidine N-(aminoiminomethyl)-4-aminobenzenesulfonamide; dimethoprim 5-(3,4-dimethoxybenzyl)-2,4-pyrimidinediamine, etc.

Not yet clear

Sulfamidine, chemical name is p-aminobenzenesulfonylaminoamidine monohydrate

1. The simultaneous use of urine alkalinizing drugs can enhance the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product and be taken up by bacteria, and the two are antagonistic to each other. It is also not suitable to be used in combination with local anesthetics containing para-aminobenzoyl, such as procaine and tetracaine. 3. For those who take estrogen contraceptives, the simultaneous long-term use of this product can reduce the reliability of contraception and increase the chance of menstrual bleeding. 4. Additive photosensitization may occur when used in combination with photosensitizing drugs. 5. Those who receive this product have an increased need for vitamin K.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid (PABA). PABA can replace this product for bacterial uptake, and the two are mutually antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxicity. Therefore, when these drugs are used simultaneously with sulfonamides, or after the use of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. When used in combination with bone marrow suppressive drugs, the adverse reactions of such drugs on the hematopoietic system may be enhanced. If there is an indication for the simultaneous use of two types of drugs, possible toxic reactions should be closely observed. 5. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 6. When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 7. When used in combination with photosensitizing drugs, additive photosensitivity may occur. 8. Patients receiving this product have an increased need for vitamin K. 9. It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product, increasing the risk of crystalluria. 10. This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, it can enhance the effect of phenylbutazone. 11. When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, resulting in increased and persistent blood drug concentrations, thereby producing toxicity. Therefore, the dose of this product may need to be adjusted during or after the use of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of sulfonamides should be monitored to help adjust the dose and ensure safe medication.